Fangran Hao1, Siyuan Wang1, Xiao Zhu1, Junsheng Xue1, Jingyun Li1, Lijie Wang1, Jian Li1, Wei Lu1,2, Tianyan Zhou3,4. 1. Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing, China. 2. State Key Laboratory of Nature and Biomimetic Drugs, Peking University, Beijing, 100191, China. 3. Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing, China. tianyanzhou@bjmu.edu.cn. 4. State Key Laboratory of Nature and Biomimetic Drugs, Peking University, Beijing, 100191, China. tianyanzhou@bjmu.edu.cn.
Abstract
PURPOSE: To investigate the anti-tumor effect of sunitinib in combination with dopamine in the treatment of nu/nu nude mice bearing non-small cell lung cancer (NSCLC) A549 cells and to develop the combination PK/PD model. Further, simulations were conducted to optimize the administration regimens. METHODS: A PK/PD model was developed based on our preclinical experiment to explore the relationship between plasma concentration and drug effect quantitatively. Further, the model was evaluated and validated. By fixing the parameters obtained from the PK/PD model, simulations were built to predict the tumor suppression under various regimens. RESULTS: The synergistic effect was observed between sunitinib and dopamine in the study, which was confirmed by the effect constant (GAMA, estimated as 2.49). The enhanced potency of dopamine on sunitinib was exerted by on/off effect in the PK/PD model. The optimal dose regimen was selected as sunitinib (120 mg/kg, q3d) in combination with dopamine (2 mg/kg, q3d) based on the simulation study. CONCLUSIONS: The synergistic effect of sunitinib and dopamine was demonstrated by the preclinical experiment and confirmed by the developed PK/PD model. In addition, the regimens were optimized by means of modeling as well as simulation, which may be conducive to clinical study.
PURPOSE: To investigate the anti-tumor effect of sunitinib in combination with dopamine in the treatment of nu/nu nude mice bearing non-small cell lung cancer (NSCLC) A549 cells and to develop the combination PK/PD model. Further, simulations were conducted to optimize the administration regimens. METHODS: A PK/PD model was developed based on our preclinical experiment to explore the relationship between plasma concentration and drug effect quantitatively. Further, the model was evaluated and validated. By fixing the parameters obtained from the PK/PD model, simulations were built to predict the tumor suppression under various regimens. RESULTS: The synergistic effect was observed between sunitinib and dopamine in the study, which was confirmed by the effect constant (GAMA, estimated as 2.49). The enhanced potency of dopamine on sunitinib was exerted by on/off effect in the PK/PD model. The optimal dose regimen was selected as sunitinib (120 mg/kg, q3d) in combination with dopamine (2 mg/kg, q3d) based on the simulation study. CONCLUSIONS: The synergistic effect of sunitinib and dopamine was demonstrated by the preclinical experiment and confirmed by the developed PK/PD model. In addition, the regimens were optimized by means of modeling as well as simulation, which may be conducive to clinical study.
Authors: Eleftherios Sachlos; Ruth M Risueño; Sarah Laronde; Zoya Shapovalova; Jong-Hee Lee; Jennifer Russell; Monika Malig; Jamie D McNicol; Aline Fiebig-Comyn; Monica Graham; Marilyne Levadoux-Martin; Jung Bok Lee; Andrew O Giacomelli; John A Hassell; Daniela Fischer-Russell; Michael R Trus; Ronan Foley; Brian Leber; Anargyros Xenocostas; Eric D Brown; Tony J Collins; Mickie Bhatia Journal: Cell Date: 2012-05-24 Impact factor: 41.582
Authors: Cesare Gridelli; Paolo Maione; Filomena Del Gaizo; Giuseppe Colantuoni; Ciro Guerriero; Carmine Ferrara; Dario Nicolella; Daniela Comunale; Alba De Vita; Antonio Rossi Journal: Oncologist Date: 2007-02
Authors: Javier Reig-López; María Del Mar Maldonado; Matilde Merino-Sanjuan; Ailed M Cruz-Collazo; Jean F Ruiz-Calderón; Victor Mangas-Sanjuán; Suranganie Dharmawardhane; Jorge Duconge Journal: Pharmaceutics Date: 2020-10-15 Impact factor: 6.321